cholesteryl ester transfer protein


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

cholesteryl ester transfer protein

Abbreviation: CETP
A protein that circulates in plasma and facilitates the chemical transfer of cholesteryl esters from high-density lipoproteins to other lipoproteins.
See also: protein
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 19995(12)0383-9.
(2.) Inazu A, Jiang XC, Haraki T, Yagi K, Kamon N, Koizumi J, et al., Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.
An StuI RFLP at the human cholesteryl ester transfer protein (CETP) locus.
Large [HDL.sub.2] can be further remodeled by cholesteryl ester transfer protein (CETP), which exchanges HDL-associated cholesteryl esters for triglycerides (TGs) from TG-rich lipoproteins (e.g., very-low-VLDL and LDL) (13, 14).
Cholesteryl ester transfer protein (CETP) transfers the cholesteryl esters from HDL to apolipoprotein B- (apoB-) containing particles in exchange for triglycerides (TG) [2] and has been considered to be a new drug target for increasing HDL-C levels.
In the agreement, the companies have agreed to co-develop BMS-795311, Bristol-Myers Squibb's preclinical small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP), which could potentially raise HDL (good cholesterol) levels and help prevent cardiovascular disease.
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor designed to fight hypercholesterolemia by raising levels of HDL.
In a 2003 study, Lipton and his colleagues identified the cholesteryl ester transfer protein (CETP) gene variant as a "longevity gene" in a population of Ashkenazi Jews.
Cholesteryl ester transfer protein (CETP) is a plasma protein that transfers lipids from 1 lipoprotein particle to another and has been a target for treatment of atherosclerosis and cardiovascular disease.
Under the expanded agreement, the companies have agreed to co-develop BMS-795311, Bristol-Myers Squibb's preclinical small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP).
Specifically, the two partners agreed to jointly develop BMS-795311, Bristol-Myers Squibb's preclinical small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP), which could potentially increase good cholesterol levels and help prevent cardiovascular disease.